MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma | Citedby Results | Blood Cancer Discovery | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma

Blood Cancer Discov (2023) 4 (5): 346–348.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy

Hamza Hashmi
Ambuj Kumar
Mohamed A. Kharfan-Dabaja
Pashna N. Munshi
Yoshihiro Inamoto
Zachariah DeFilipp
Bhagirathbhai Dholaria
Tania Jain
Miguel-Angel Perales
Paul A. Carpenter
Mehdi Hamadani
Binod Dhakal
Saad Z. Usmani

Transplantation and Cellular Therapy (2024) 30 (8): 750.

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Huishou Fan
Bing Wang
Lihui Shi
Ni Pan
Wenqiang Yan
Jingyu Xu
Lixin Gong
Lingna Li
Yuntong Liu
Chenxing Du
Jian Cui
Guoqing Zhu
Shuhui Deng
Weiwei Sui
Yan Xu
Shuhua Yi
Mu Hao
Dehui Zou
Xiequn Chen
Lugui Qiu
Gang An

Clinical Cancer Research (2024) 30 (6): 1131.